How immune receptor clustering affects the ability of NK cells to kill cancer cells
Role of immune receptor clustering in controlling efficacy of antibody-dependent FcγRIIIa-mediated cytotoxicity by NK cells
This study is looking at how grouping certain immune receptors can help natural killer (NK) cells work better to fight off viruses and cancer, with the hope that it will lead to improved treatments for patients using antibody therapies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10763811 on NIH RePORTER |
What this research studies
This research investigates the role of immune receptor clustering in enhancing the effectiveness of natural killer (NK) cells, which are crucial for eliminating virus-infected and cancer cells. The study focuses on how the clustering of FcγRIIIa receptors, which interact with antibodies bound to target cells, influences NK cell activity. By understanding these mechanisms, the research aims to improve antibody-dependent cellular cytotoxicity (ADCC), a process that could lead to better cancer treatments. Patients may benefit from insights that could enhance the efficacy of antibody therapies in fighting malignancies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers or autoimmune diseases who may benefit from enhanced antibody therapies.
Not a fit: Patients with conditions unrelated to immune receptor activity or those not receiving antibody-based treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by improving the ability of NK cells to target and destroy cancer cells.
How similar studies have performed: Previous research has shown promising results in enhancing NK cell activity through receptor clustering, indicating a potential for success in this approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Sykulev, Yuri — Thomas Jefferson University
- Study coordinator: Sykulev, Yuri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.